Catalog No.S8132 Synonyms: (-)-Deguelin, (-)-cis-Deguelin

For research use only.

Deguelin, a natural product isolated from plants in the Mundulea sericea family, is an PI3K/AKT Inhibitor.

Deguelin Chemical Structure

CAS No. 522-17-8

Selleck's Deguelin has been cited by 3 Publications

Purity & Quality Control

Choose Selective Akt Inhibitors

Other Akt Products

Biological Activity

Description Deguelin, a natural product isolated from plants in the Mundulea sericea family, is an PI3K/AKT Inhibitor.
PI3K [1] Akt [1]
In vitro

Deguelin downregulates Akt phosphorylation in leukaemia cell lines with an active PI3K/Akt axis. At 10 or 100 nmol/l, deguelin is effective in inhibiting Akt phosphorylation. Total Akt expression is unchanged by deguelin. Moreover, deguelin does not affect the expression or the phosphorylation levels of either p44/42 or p38 MAP kinases in U937 cells. Deguelin increases sensitivity of human leukaemia cells to chemotherapeutic drugs. Deguelin dephosphorylates Akt and increases cytarabine sensitivity of AML blasts but not of CB CD34+. Deguelin, when employed for 24 h at 10 nmol/l, causes an S phase arrest of U937 cells, with interference of progression to G2/M phase. While employed alone up to a concentration of 10 nmol/l for 24 h, Deguelin does not significantly increase the apoptotic rate of U937 cells[1].

In vivo Deguelin inhibits in vivo angiogenesis of chick chorioallantoic membrane (CAM) without cytotoxic effect and significantly reduces laser-induced CNV in a mouse model of AMD without significant retinal toxicity[2]. It exhibited significant anti-tumorigenesis and anti-proliferative activity in various types of cancer both in vitro and in vivo. In pre-clinical trials, deguelin markedly decreased the tumor incidence. Topically-administered deguelin significantly suppressed the multiplicity of skin tumors with UVB-induction, indicating its effect as a potential cancer chemopreventive agent. In A/J mice, deguelin clearly reduced the tumor multiplicity and volume, as well as the overall tumor burden with exposure to the tobacco-specific carcinogen benzo(a)pyrene (Bap) and other carcinogens, with no detectable toxicity. Nevertheless, the toxicity of deguelin over a certain dose should not be neglected. Treatment with deguelin, a potential mitochondria complex I inhibitor, reduced tyrosine hydroxylase-positive neurons, leading to Parkinson’s disease. Kim et al shows that deguelin promoted a PD-like syndrome, mainly by Src/STAT signaling, since α-synuclein (a key protein function in the pathogenesis of PD) was phosphorylated by deguelin-activated Src[3].

Protocol (from reference)

Cell Research:[1]
  • Cell lines: U937 cells
  • Concentrations: 1 nM, 10 nM, 100 nM
  • Incubation Time: 24 h
  • Method: Flow cytometric analysis of cell cycle in response to deguelin. Cells are incubated with the indicated concentrations of deguelin for 24 h, then analysed for DNA content and for the percentage of cells in specific phases of the cell cycle by means of PI staining, whereas for detection of apoptotic cells the Annexin-FITC staining was employed. For this reason, the sum of apoptotic cells plus cells in various phases of the cell cycle exceeds 100%.
Animal Research:[4]
  • Animal Models: A/J mice
  • Dosages: 5.0 or 10.0 mg/kg
  • Administration: by gavage

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 394.42


CAS No. 522-17-8
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC1(C=CC2=C(O1)C=CC3=C2OC4COC5=CC(=C(C=C5C4C3=O)OC)OC)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Deguelin | Deguelin supplier | purchase Deguelin | Deguelin cost | Deguelin manufacturer | order Deguelin | Deguelin distributor